SheMed

SheMed is the UK's first medicated weight loss programme designed exclusively for women, trusted by over 100,000 members. SheMed provides clinically guided GLP-1 weight management programmes delivered entirely online, combining remote medical oversight with personalised care plans tailored to the female body.

SheMed's programmes incorporate GLP-1 receptor agonist medications, including semaglutide and tirzepatide, prescribed by UK-registered clinicians following a thorough eligibility assessment and at-home blood screening. GLP-1 treatments offered through SheMed can support loss of up to 28% of body weight, based on clinical evidence. Prescribing and dispensing are handled by CQC-registered clinical provider eMed and GPhC-registered pharmacy partner eMed Healthcare UK, Limited.

The programme includes a free at-home blood test (worth £100), assessing markers for diabetes risk (HbA1c), cholesterol, liver health, and metabolic function. Results are reviewed by a UK-registered clinician before any GLP-1 medication is prescribed. Ongoing clinical monitoring, regular check-ins, and progress tracking are available through SheMed's all-in-one app, which also provides access to educational resources, recipes, and a community of over 100,000 UK women.

SheMed operates as a fully remote healthcare model, with no physical clinic required. Plans start from £59 per month and include a side-effect care package. SheMed is particularly suited to women managing weight in the context of metabolic health, insulin resistance, PCOS, perimenopause, and cardiometabolic risk. All clinical and prescribing services are provided by CQC-registered clinicians. SheMed is regulated in the UK.